MedTrace Logo

Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia

NCT03850730 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-09-08

No results posted yet for this study

Summary

Investigators will test the value of very low dose Pazopanib administered to patients with hereditary hemorrhagic telangiectasia for the reduction in the severity of nose bleeds in those with frequent and long duration bleeding episodes.

Conditions

  • Hereditary Hemorrhagic Telangiectasia
  • Epistaxis

Interventions

DRUG

Pazopanib

Active pharmaceutical ingredient plus excipients filled into a capsule for the lower dosing necessary in this study

Sponsors & Collaborators

  • University of North Carolina

    collaborator OTHER

  • Cure HHT

    lead OTHER

Principal Investigators

  • Raj Kasthuri, MD · University of North Carolina

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2025-06-30
Completion
2025-12-31
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03850730 on ClinicalTrials.gov